Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
31 October 2019 - 7:05AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company developing novel precision antibacterials
to treat serious drug-resistant infections, today announced the
appointment of David Altarac, M.D., MPA as Chief Medical Officer,
effective November 4, 2019. In conjunction, Robin Isaacs, M.D., who
has served as the Company’s Chief Medical Officer since July 2015,
announced his plans to retire at the end of 2019. Dr. Isaacs will
continue as an advisor to the Company as the Phase 3 programs move
toward regulatory review.
Dr. Altarac is an industry leader in R&D
across multiple therapy areas and is recognized as a strategic
biopharmaceutical leader. Over the course of a 20+ year career, he
has led multiple new drug approvals in major global markets as well
as many product extensions in global emerging and secondary
markets.
As Chief Medical Officer, Dr. Altarac will be
responsible for leading clinical development for Entasis’ lead
programs, sulbactam-durlobactam and zoliflodacin, both of which are
undergoing global Phase 3 trials. In addition, he will lead Medical
Affairs, Pharmacovigilance, Quality and Regulatory Affairs. Dr.
Altarac will also lead the advancement of ETX0282CPDP clinical
development and the expansion of the Company’s pipeline of
pathogen-targeted antimicrobials.
Manos Perros, Chief Executive Officer, Entasis
Therapeutics, said, “We are truly delighted to welcome David to the
team. As our lead programs advance through late-stage development,
David’s broad expertise and experience in biopharmaceutical R&D
will help drive our strategy and prepare for commercialization,
while ensuring quality and patient safety. We thank Robin for his
years of dedication, insightfulness, and expertise that drove
forward our pathogen-targeted antibacterial programs and look
forward to continuing to work with him in his new capacity.”
Dr. Altarac added, “Entasis is spearheading a
new model for antibiotic development and commercialization, making
use of the latest technologies to deliver transformative treatments
for patients with the highest unmet medical needs. I look forward
to working closely with the team to translate ground-breaking
science into meaningful new antimicrobials and to continue building
our pipeline of innovative programs.”
Prior to joining Entasis, Dr. Altarac was Senior
Vice President and Head of Global Regulatory Affairs, Global Drug
Safety and R&D Quality and Compliance at Shire. Prior to
joining Shire, Dr. Altarac spent two years as VP, Regulatory
Affairs at NeoStem and more than 13 years at Merck & Company,
where he served on multiple senior leadership teams and held roles
of increasing responsibility. David holds an M.D. degree from New
York Medical College, Valhalla, New York, a Master of Public
Administration (M.P.A.) degree from New York University, and a B.A.
in Chemistry from the State University of New York at Binghamton,
New York. He completed his residency in internal medicine and
fellowship in Infectious Diseases at Beth Israel Medical Center in
New York.
About Entasis Entasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including
sulbactam-durlobactam (targeting Acinetobacter
baumannii infections), zoliflodacin (targeting Neisseria
gonorrhoeae), and ETX0282CPDP
(targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information,
visit www.entasistx.com
Entasis Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Entasis’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Many factors may cause differences
between current expectations and actual results, including
unexpected safety or efficacy data observed during non-clinical or
clinical studies, clinical site activation rates or clinical trial
enrolment rates that are lower than expected and changes in
expected or existing competition, changes in the regulatory
environment, failure of Entasis’ collaborators to support or
advance collaborations or product candidates and unexpected
litigation or other disputes. Many of these factors are beyond
Entasis’ control. These and other risks and uncertainties are
described more fully in the Entasis’ filings with the U.S.
Securities and Exchange Commission, including the section titled
“Risk Factors” contained therein. Forward-looking statements
contained in this announcement are made as of this date, and except
as required by law, Entasis assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Entasis Company Contact Kyle Dow Entasis
Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactTram Bui The Ruth
Group646-536-7035tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2024 to May 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From May 2023 to May 2024